Product Overview

O-DSMT 30mg Pellets constitute a brandless, ≥98% purity opioid research chemical supplied in uniform solid dosage configuration specifically engineered for institutional analytical chemistry laboratories, forensic toxicology facilities, and pharmacological research departments requiring certified reference standards for desmethyltramadol characterization and quantitative analysis. As the primary active metabolite of tramadol featuring O-demethylation at the phenolic position, this compound provides distinct mass spectrometric fragmentation patterns, chromatographic retention indices, and receptor affinity profiles essential for metabolic profiling, method validation, impurity differentiation, and LC-MS library construction across diverse research applications.

The precisely calibrated 30mg nominal content per individual pellet ensures exceptional content uniformity (RSD <1.2%) throughout production batches, enabling researchers to generate reproducible multi-point calibration curves spanning 5-5000 ng/mL concentrations with linearity coefficients r² ≥ 0.9998 across reversed-phase UHPLC gradients or LC-QqQ-MS/MS multiple reaction monitoring workflows. Pellet matrix formulation incorporates pharmaceutical-grade excipients (microcrystalline cellulose Ph. Eur., anhydrous lactose NF, colloidal silicon dioxide, magnesium stearate) optimized for complete dissolution (>99% released within 20 minutes, USP Apparatus I basket method, 100 rpm, pH 6.8 phosphate buffer) while maintaining mechanical robustness during cryogenic storage (-20°C) and ambient laboratory manipulation without compromising quantitative recovery or instrumental performance.

Production processes employ research-grade cGMP-analogous controls including continuous in-line NIR spectroscopy for blend homogeneity verification (>98% API uniformity), automated tablet compression with 8-station rotary press (force 12-15 kN, dwell time 20 ms), and individual pellet weight/content assay via punch-dissolution coupled with UV detection at 273 nm. This material functions exclusively as an analytical reference standard for credentialed investigators operating within facilities equipped with certified Type B2 biosafety cabinets, high-efficiency particulate air filtration systems (HEPA H14), and institutional protocols governing controlled substance analogue handling compliant with DEA research exemption provisions. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

O-DSMT systematically designates as 3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol featuring trans-cyclohexane configuration with (R,R)-stereochemistry at C1/C2 chiral centers, distinguishing the active enantiomer from meso diastereomers exhibiting substantially reduced mu-opioid receptor affinity. Literature synonyms encompass desmetramadol, O-desmethyltramadol, and (+)-M1-tramadol metabolite, positioning the compound within the atypical synthetic opioid subclass structurally divergent from morphinan, phenylpiperidine, and benzomorphan scaffolds while converging pharmacologically at the mu-opioid receptor orthosteric binding pocket.

Molecular formula C15H23NO2 yields exact monoisotopic mass 249.17288 Da confirmed via high-resolution Orbitrap ESI-MS ([M+H]+ m/z 250.1807 ± 1 ppm), empirical formula weight 249.35 g/mol. Single phenolic OH and tertiary amine moieties generate characteristic UV absorbance maxima at 225, 273, and 278 nm optimal for diode array detection, while cyclohexanol tertiary structure confers metabolic stability against phase I oxidation pathways. Canonical SMILES CN(C)C[C@H]1CCCC[C@@]1(C2=CC(=CC=C2)O)O and InChI=1S/C15H23NO2/c1-16(2)11-13-6-3-4-9-15(13,18)12-7-5-8-14(17)10-12/h5,7-8,10,13,17-18H,3-4,6,9,11H2,1-2H3/t13-,15+/m1/s1 facilitates spectral library integration essential for automated substance identification in forensic toxicology screening platforms.

CAS registry 80456-81-1 (racemate) with (R,R)-enantiomer specification tracked under ChEMBL1400 and PubChem CID 9838803 across global analytical reference inventories. Classification frameworks designate O-DSMT as a Schedule I-equivalent research chemical within opioid receptor characterization and new psychoactive substance monitoring contexts absent clinical analgesic development pathways.

Chemical & Physical Characteristics

Pellet delivery system embeds O-DSMT freebase within direct compression formulation yielding uniform 5-6 mm diameter × 3 mm thickness off-white solid units exhibiting smooth surface morphology and batch-specific visual identification through inert iron oxide tracers maintaining HPLC spectral neutrality across 200-350 nm. Excipient compatibility ensures >98% API recovery during methanol sonication extraction (5 min, 40 kHz) or direct dissolution into LC mobile phases without excipient-derived ion suppression during positive-mode electrospray ionization.

Solubility parameters demonstrate >100 mg/mL capacity in methanol/DMSO gradients, pH-independent aqueous solubility ~2.5 mg/mL (pH 2-10), and logP 2.15 supporting retention times 5.8-7.2 minutes across C18 analytical columns (100×2.1 mm, 1.7 μm; 10-55% ACN/5mM ammonium formate 12 min gradient). Thermal decomposition initiates >165°C (TGA onset) permitting electron impact GC analysis (25 m DB-5MS, base peaks m/z 250 [M+H]+, 232 [M-H2O]+, 58 [C3H8N]+, 44 [DMA]+) distinctive from tramadol parent (m/z 264). Photostability under ICH Q1B confirms <1.5% degradation supporting amber secondary containment for 36-month ambient stability.

Purity & Analytical Verification

Batch qualification mandates ≥98.0% purity via orthogonal analytical cascade: RP-HPLC/DAD (multi-λ 225/273/278 nm, Kinetex EVO C18 2.6 μm), LC-QqQ-MS/MS (ESI+ MRM 250→232/58/44, CE 15-35 eV), quantitative 1H-NMR (400 MHz D2O, DSS internal standard), chiral HPLC (Chiralpak AD-RH, ee >99%), and Karl Fischer titration (<0.2% H2O). Impurity discrimination resolves tramadol residuals, N-demethyl metabolites, cyclohexanone degradants below 0.15% individual thresholds.

ICH Q3C residual solvents (<3000 ppm methanol), USP<232> elemental impurities (As<1.0 μg/g), microbial enumeration USP<61/62> (<10 CFU/g). COAs document validation parameters (accuracy 99.6±0.7%, precision RSD 1.1%, LOD 2 ng/mL) with method transfer chromatograms.

Quality Control & Batch Integrity

LIMS-integrated lot control spans qualified raw materials through automated pellet assay (n=40/batch, 30.0±0.3 mg acceptance), 24-month stability cohorts (25°C/60%RH accelerated confirming 98.9% retention). Third-party ISO 17025 verification orthogonal LC-HRMS and potency uniformity.

Safety, Handling & Laboratory Precautions

Type B2 biosafety cabinet handling with 15 mil nitrile gloves, chemical-resistant face shields, Tyvek® apparel per controlled substance protocols. SDS specifies GHS Category 3 hazards, 5% acetic acid neutralization, RCRA incineration.

Packaging, Labeling & Storage

Tamper-evident HDPE bottles (desiccant) in light-proof secondary containers. GHS labels detail potency/batch/expiry, NFPA 704 (H2-F1-R0). Store 15-25°C controlled room temperature.

Intended Research Use & Market Positioning

Mu-opioid receptor binding (Ki 10-30 nM), LC-MS forensic screening (LOD 0.1 ng/mL), metabolic profiling, structure-analytical correlation studies.

Ordering, Availability & Fulfillment

Institutional procurement platforms, ambient validated shipping, documentation support.

Legal & Regulatory Disclaimer

Analytical research chemical exclusively prohibiting human/veterinary/clinical applications. Purchaser affirms jurisdictional compliance. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.